Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-560
- Development stage
- Discontinued
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABT-560 is a small molecule neuronal nicotinic receptor (NNR) modulator that primarily targets the α4β2 and α5 subunits of the nicotinic acetylcholine receptor. It was developed for potential use in treating cognitive deficits and other central nervous system (CNS) disorders. The drug showed promise in preclinical models relevant to cognition but was discontinued after early clinical development. The mechanism of action involves modulation of specific neuronal nicotinic receptors implicated in cognitive function[1][2][3][4][5].
02
Targets
α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)α4α5β2 nAChR (α4α5β2 nicotinic receptor)
Beyond the preview
Go deeper on ABT-560.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-560.